Valuation: Jade Biosciences, Inc.

Market Cap 1.24B 1.08B 999M 920M 1.73B 119B 1.77B 11.94B 4.69B 58.4B 4.65B 4.55B 201B P/E 2026 *
-8.02x
P/E 2027 * -8.1x
Enterprise Value 985M 861M 794M 732M 1.38B 94.83B 1.41B 9.49B 3.73B 46.44B 3.7B 3.62B 160B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.17%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jade Biosciences, Inc.

1 day+1.86%
1 week-0.43%
Current month-6.12%
1 month+23.65%
3 months-8.71%
6 months+41.90%
Current year+35.19%
1 week 19.4
Extreme 19.4
22.58
1 month 17.54
Extreme 17.54
23.49
Current year 12.45
Extreme 12.45
28
1 year 6.67
Extreme 6.67
28
3 years 6.56
Extreme 6.565
28
5 years 6.56
Extreme 6.565
28
10 years 6.56
Extreme 6.565
28
Manager TitleAgeSince
Chief Executive Officer 50 28/04/2025
Director of Finance/CFO 38 14/07/2025
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Chairman 57 28/04/2025
Director/Board Member 39 28/04/2025
Director/Board Member 48 28/04/2025
Date Insider Type Main position Quantity % Market Cap.
25/6/26 Free

Director

47,675 0.0966%
9/6/26
Fairmount Funds Management LLC
FreeCompany 34,843 0.0706%
9/6/26 Free

Director

34,843 0.0706%
Change 5-day change 1-year change 3-year change Capi.($)
+1.86%-0.43%+119.35% - 1.24B
+3.90%-0.39%+376.72%+599.59% 39.58B
-1.70%+4.46%+7.46%+57.67% 34.69B
-2.01%-0.76%+26.35%-6.83% 34.42B
+0.06%+0.34%+2.32%+29.30% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+68.48%+117.39% 15.36B
+1.12%+1.91%+15.90%+19.65% 14.05B
0.00%+1.36%+15.74%-30.62% 13.02B
-0.08%-3.01%+1,271.69%+649.69% 11.76B
Average +0.36%-0.01%+211.56%+179.48% 20.74B
Weighted average by Cap. +0.25%+0.35%+171.09%+187.42%

Financials

2026 *2027 *
Net sales - -
Net income -173M -151M -140M -129M -243M -16.68B -248M -1.67B -657M -8.17B -650M -636M -28.12B -191M -167M -154M -142M -268M -18.41B -274M -1.84B -725M -9.02B -718M -702M -31.04B
Net Debt -254M -222M -204M -188M -355M -24.41B -363M -2.44B -961M -11.96B -952M -931M -41.16B -300M -262M -242M -223M -421M -28.92B -430M -2.89B -1.14B -14.16B -1.13B -1.1B -48.75B
Logo Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Employees
55
Date Price Change Volume
17/07/26 USD 20.86 +1.86% 659,521
16/07/26 USD 20.48 -6.31% 1,285,003
15/07/26 USD 21.86 +2.44% 804,004
14/07/26 USD 21.34 +0.19% 1,218,118
13/07/26 USD 21.30 +1.67% 1,587,752
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
20.86USD
Average target price
48.50USD
Spread / Average Target
+132.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JBIO Stock